Showing results (131-140 of 345) with videos related to
Sort By:
Pageof 35
Journal of General Internal Medicine|January 30, 2008
Cost-effectiveness of chlorthalidone, amlodipine, and lisinopril as first-step treatment for patients with hypertension: an analysis of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)Paul A Heidenreich, Barry R Davis, Jeffrey A Cutler, et al.American Heart Journal|September 20, 2005
Association of beta-blocker use with mortality among patients with congestive heart failure in the Cardiovascular Health Study (CHS)Jeannie D Chan, Thomas D Rea, Nicholas L Smith, et al.Prehospital and Disaster Medicine|December 16, 2014
Burden of cardiovascular morbidity and mortality following humanitarian emergencies: a systematic literature reviewKaitlin G Hayman, Davina Sharma, Robert D Wardlow, et al.Drug Safety|June 9, 2017
An Algorithm to Identify Generic Drugs in the FDA Adverse Event Reporting SystemGeetha Iyer, Sathiya Priya Marimuthu, Jodi B Segal, et al.Journal of Comparative Effectiveness Research|July 8, 2017
Patient-relevant outcomes associated with generic tamsulosin, levothyroxine and amphetamine in the FDA Adverse Event Reporting System: a pilot studySathiya Priya Marimuthu, Geetha Iyer, Jodi B Segal, et al.Circulation. Cardiovascular Quality and Outcomes|February 4, 2010
Does Ginkgo biloba reduce the risk of cardiovascular events?Lewis H Kuller, Diane G Ives, Annette L Fitzpatrick, et al.Indian Dermatology Online Journal|August 20, 2025
Exploring Trace Metal Imbalances: Serum Levels of Zinc, Selenium, Copper, Lead, Cadmium, and Mercury, and their Ratios in Acne Vulgaris Patients: An Analytical Cross-sectional StudySoumya Agarwal, Shivani Singh, Sonal Singh, et al.Journal of the American Geriatrics Society|September 29, 2004
Risk of congestive heart failure in an elderly population treated with peripheral alpha-1 antagonistsChris L Bryson, Nicholas L Smith, Lewis H Kuller, et al.Seminars in Thrombosis and Hemostasis|October 23, 2012
Underreporting of hemorrhagic and thrombotic complications of pharmaceuticals to the U.S. Food and Drug Administration: empirical findings for warfarin, clopidogrel, ticlopidine, and thalidomide from the Southern Network on Adverse Reactions (SONAR)Thomas J Moore, Charles L BennettJournal of Clinical Epidemiology|April 8, 2009
A pragmatic-explanatory continuum indicator summary (PRECIS): a tool to help trial designersKevin E Thorpe, Merrick Zwarenstein, Andrew D Oxman, et al.Pageof 35